Midwest Annual Conference

Location: Rosemont, IL
Date: October 15-19, 2013

Meeting Overview

Venue:
Donald E. Stephens Convention Center
Primary Audience:
Primary Care
Credits:
Refer to the Accreditation Tab

Online registration for this event is now closed so that we may prepare for the program. On-site registration opens Wednesday, October 16, 2013 at 7am.

What’s most important to you is important to us.

The demands and challenges you face every day within your practice are constantly changing, so we’re changing with you.

We’ve taken the feedback of clinicians in your region and across the country to launch an all-new Annual Conference, beginning with Pri‑Med Midwest this fall.

Pri‑Med has expanded its partnership with the American College of Physicians (ACP), and in collaboration with the ACP we will be unveiling an entirely new cutting-edge CME curriculum. The CME sessions will include the latest treatments and therapies, such as:

  • Obesity in America, presented by the Dietary Counselor and Lifestyle Coach from “The Biggest Loser”
  • High Yield Office Interventions for Common Orthopedic Aches and Pains
  • ID Updates in Office-Based Primary Care
  • Test Your Skills in Difficult Cases: Nephrology (Chronic Renal Failure), Hypertension, and Atrial Fibrillation

View the full session schedule»

But that’s not all…

In addition to over 35 new educational sessions, there are many new components of the conference that were created with you in mind.

  • Three renowned Keynote Speakers including Dr Michael Dansinger, a weight loss and nutrition consultant for NBC’s “The Biggest Loser.”
  • SAFE Opioid Prescribing track featuring a faculty meet and greet and book signing
  • The ability to purchase a full set of the Annual Conference curriculum printed slides on-site for $10 on a first‑come first‑served basis
  • The opportunity to earn AANP contact hours of continuing education

Earn up to 26 AMA PRA Category 1 Credits™ or 26 AANP contact hours of continuing education.

Register for Pri‑Med Midwest by: Your price**
June 14 $30
August 9 $40
September 20 $55
October 12 $75
On-site at Pri‑Med Midwest $100
Watch this video for a sneak peek of Dr. Michael Dansinger speaking on obesity in America.video

To date, the following organizations provided educational grants to support a portion of this activity: Lilly USA, LLC and REMS Program Companies.

*Primary Care Updates tracks are sponsored by pmiCME and are produced independently of and are not affiliated with the American College of Physicians. This is a limited-capacity ticketed event available on a first-come, first-served basis and by registration.

**Price represents online registration; registration by phone is an additional $10.

Earn up to 26 AMA PRA Category 1 Credits™ or 26 AANP contact hours of continuing education October 16–19, 2013, at Primary Care Updates and Annual Conference. Earn up to an additional 9.25 credits on October 15, 2013, at Primary Care Updates and Integrated Approaches to Cardiometabolic Care; seating is extremely limited for these two programs.

Pri-Med Midwest Mobile App--get it today!

 

Comprehensive CME Program
Pri-Med doctor

Primary Care Updates*
October 15, 2013 | Morning
CME sessions that focus on cardiometabolic disease-specific treatment and management approaches. Seating is extremely limited.

Integrated Approaches to Cardiometabolic Care
October 15, 2013 | Afternoon
Innovative new CME sessions for PCPs, cardiologists, and endocrinologists who jointly manage patients with complex cardiometabolic conditions. Case studies, lectures, and a panel discussion will cover treatment decisions for high-risk patients.

Primary Care Updates*
October 16, 2013
A multi-track day of CME programs to supplement your education.

Annual Conference
October 17–19, 2013
An entirely new cutting-edge CME curriculum developed in collaboration with the American College of Physicians.


Educational Symposia
Accredited CME sessions to expand your learning during breaks from the core ACP curriculum.


Industry-sponsored Opportunities

Exhibit Hall
Have face-to-face conversations with industry professionals, gain helpful takeaways, and experience engaging floor activities such as live demonstrations, outside your office hours. Learn More »

Presentation Theaters
Live discussions led by prominent medical thought leaders. Get an in-depth look at the latest tools and treatment options.


Registration for symposia and presentation theaters will open on August 20, 2013.

Presentation Theaters are not offered for CME credit nor is the content planned or reviewed by pmiCME or ACP.

 

Sessions & Syllabus

For your convenience, we have printer-friendly syllabus slides available for you to download.

Print Primary Care Updates Syllabus

CLOSE  X  
Registration & Continental Breakfast
CLOSE  X  
Opening Remarks
CLOSE  X  
Practical Pointers for the Cardiometabolic Patient
Learning Objectives:
  1. Review evidence-based screening recommendations for diabetes, while understanding how to best employ nutritional guidelines to better care for patients at risk for or with diabetes.
  2. Discuss the cardiac risk consequences associated with CKD and establish appropriate management plans to ensure improved health outcomes.
  3. Define the differences in cardiac risk scoring and the clinical applications for your practice.
  4. Assess and employ enhanced patient communication strategies designed to improve patient outcomes.
  5. Discuss the importance of early clinical data on the interrelationships between circadian rhythms and metabolism.
Faculty:
  1. Pamela Kushner, MA, MD, FAAFP, Clinical Professor, Department of Family Medicine, University of California, IrvineIrvine, CA (Bio)
CLOSE  X  
Networking Break
CLOSE  X  
Managing Hypertension and Obesity through Therapeutics and Lifestyle Modifications
Learning Objectives:
  1. Outline current guidelines on the diagnosis, management and treatment of patients who are obese;
  2. Identify the constellation of cardiovascular risk markers in diabetic, insulin resistant, metabolic syndrome and/or obese patients;
  3. Understand the comprehensive approach to the treatment of obesity and hypertension.
Faculty:
  1. James Underberg, MD, FASH , FNLA , MS , FACP , FACPM (Bio)
  2. Robert Gleeson, MD , FACP , FNLA
CLOSE  X  
New Advancements in Managing the Patient with Severe Dyslipidemia
Learning Objectives:
  1. Review the potential role for diagnostic panels and important makers to improve CV risk assessment in complex patient populations
  2. Define treatment goals for patients with mixed dyslipidemia based on the latest guidelines for lipid management issued by the NCEP, NLA and other relevant treatment recommendations
  3. Utilize effective treatment strategies for the management of dyslipidemia in patients with multiple cardiometabolic risk factors;
Faculty:
  1. Alan Brown, MD, FACC, FNLA , FAHA (Bio)
  2. Joseph Saseen, PharmD, FCCP, BCPS
CLOSE  X  
Exploring the Interrelationships of Cardiometabolic Risk and How to Best Manage the Patient Who Presents With Metabolic and Cardiovascular Disease
Explore current insights on the interrelationships between insulin resistance and cardiovascular disease and learn how best to mitigate risk and prevent disease progression. World-renowned experts in endocrinology, cardiology and primary care will deliver invaluable perspectives on evidence-based approaches to effectively manage cardiometabolic risk and disease. The faculty panel will debate and discuss current clinical strategies which best address the challenges of optimally managing cardiometabolic risk, achieving an accurate diagnosis, and best ways to integrate treatments that reduce morbidity and mortality.
Learning Objectives:
  1. Explain the interrelationships between various cardiometabolic risk factors such as obesity, pre-diabetes, diabetes, hypertension and dyslipidemia, and their impact on cardiovascular disease and comorbid conditions.
  2. Utilize current guidelines and expert opinion to formulate an effective treatment plan for patients at risk or with complex cardiometabolic conditions in order to reduce morbidity and mortality associated with metabolic and cardiovascular disease.
Faculty:
  1. Yehuda Handelsman, FNLA , MD , FACP , FACE, Private Practice, EndocrinologistTarzana, CA, Medical Director & Principal Investigator, Metabolic Institute of AmericaTarzana, CA (Bio)
  2. Peter Libby, FACC , MD, Chief of Cardiovascular Medicine, Brigham and Women's HospitalBoston, MA, Mallinckrodt Professor of Medicine, Harvard Medical SchoolBoston, MA (Bio)
  3. Pamela Kushner, MA, MD, FAAFP, Clinical Professor, Department of Family Medicine, University of California, IrvineIrvine, CA (Bio)
CLOSE  X  
Networking Break
CLOSE  X  
Managing the Clinical Complexities of Cardiometabolic Disease: What about the Cardiovascular Issues?
This interactive case-based workshop will assess the complexities of cardiovascular issues which often present in complex cardiometabolic patients, with a specific focus on the management of dyslipidemia, hypertension, and chronic kidney disease in the obese, diabetic patient. Experts will review the best non-pharmacologic and pharmacologic strategies to help patients achieve target goals.
Learning Objectives:
  1. Establish clinical priorities for the management of cardiovascular issues commonly seen in the complex cardiometabolic patient, while considering important interrelationships that may influence your treatment plan.
  2. Translate evidence-based clinical strategies in the prevention, screening, and treatment of comorbid cardiovascular issues in the metabolic patient, so as to improve patient health outcomes.
Faculty:
  1. Yehuda Handelsman, FNLA , MD , FACP , FACE, Private Practice, EndocrinologistTarzana, CA, Medical Director & Principal Investigator, Metabolic Institute of AmericaTarzana, CA (Bio)
  2. Pamela Kushner, MA, MD, FAAFP, Clinical Professor, Department of Family Medicine, University of California, IrvineIrvine, CA (Bio)
  3. Paul Rosenblit, MD, PhD , FACE , FNLA, Clinical Professor of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of California, IrvineIrvine, CA, Co-Director, Diabetes Out-Patient Clinic, UCI Medical CenterOrange, CA (Bio)
CLOSE  X  
Managing the Clinical Complexities of Cardiometabolic Disease: What about Glucose Control Issues?
This interactive, case-based workshop will assess the complexities of glucose control, with a specific focus on strategies to best manage dysglycemia in patients with co-morbid disease. Experts will discuss the most effective non pharmacologic and pharmacologic approaches for helping patients achieve glycemic target goals.
Learning Objectives:
  1. Establish clinical priorities for the management of glycemic issues commonly seen in the complex cardiometabolic patient, while considering important interrelationships which may impact your choice of treatments.
  2. Determine how to best employ antihyperglycemic therapies in a patient not at goal in the midst of comorbid issues, including obesity, cardiovascular problems, and impaired renal function.
Faculty:
  1. Peter Libby, FACC , MD, Chief of Cardiovascular Medicine, Brigham and Women's HospitalBoston, MA, Mallinckrodt Professor of Medicine, Harvard Medical SchoolBoston, MA (Bio)
  2. Pamela Kushner, MA, MD, FAAFP, Clinical Professor, Department of Family Medicine, University of California, IrvineIrvine, CA (Bio)
  3. James Underberg, MD, FASH , FNLA , MS , FACP , FACPM, Clinical Assistant Professor of Medicine, NYU Medical SchoolNew York, NY, NYU Center for Prevention of Cardiovascular DiseaseNew York, NY, Director, Bellevue Hospital Lipid ClinicNew York, NY (Bio)
CLOSE  X  
Networking Break
CLOSE  X  
Call to Action: Integrated Approaches to Managing the Complex Cardiometabolic Patient
A panel of world-renowned experts will discuss key insights from the day’s curriculum, as well as pertinent findings from case presentations, so as to provide important clinical pearls that can be applied to clinical practice. The discussion will include a "Call to Action" for improved integrated and collaborative care of the cardiometabolic patient.
Learning Objectives:
  1. Discuss challenges of managing the complex cardiometabolic patient and ways in which a team-based approach will reduce morbidity/mortality and improve patient outcomes.
  2. Develop effective communication strategies and collaborative care processes that will augment primary care provider/specialist relationships, with the goal of improving health outcomes of the cardiometabolic patient.
Faculty:
  1. Yehuda Handelsman, FNLA , MD , FACP , FACE, Private Practice, EndocrinologistTarzana, CA, Medical Director & Principal Investigator, Metabolic Institute of AmericaTarzana, CA (Bio)
  2. Peter Libby, FACC , MD, Chief of Cardiovascular Medicine, Brigham and Women's HospitalBoston, MA, Mallinckrodt Professor of Medicine, Harvard Medical SchoolBoston, MA (Bio)
  3. Pamela Kushner, MA, MD, FAAFP, Clinical Professor, Department of Family Medicine, University of California, IrvineIrvine, CA (Bio)
  4. JoAnne Foody, MD, FACC, FAHA, Associate Professor of Medicine, Harvard Medical SchoolBoston, MA, Director, Cardiovascular Wellness Program, Brigham and Women's HospitalBoston, MA (Bio)
  5. James Underberg, MD, FASH , FNLA , MS , FACP , FACPM, Clinical Assistant Professor of Medicine, NYU Medical SchoolNew York, NY, NYU Center for Prevention of Cardiovascular DiseaseNew York, NY, Director, Bellevue Hospital Lipid ClinicNew York, NY (Bio)
  6. Paul Rosenblit, MD, PhD , FACE , FNLA, Clinical Professor of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of California, IrvineIrvine, CA, Co-Director, Diabetes Out-Patient Clinic, UCI Medical CenterOrange, CA (Bio)
CLOSE  X  
Faculty & Attendee Networking Reception
Primary Care Updates 1
6:30AM
 
7:00AM
 
7:30AM
 
8:00AM
 
8:30AM
 
9:00AM
 
9:30AM
 
10:00AM
 
10:30AM
 
6:30 AM-7:30 AM - Registration & Continental Breakfast
 
 
 
7:30 AM-7:45 AM - Opening Remarks
7:45 AM-9:15 AM
Practical Pointers for the Cardiometabolic Patient
 
 
 
 
 
 
 
 
 
 
 
10:45 AM-11:00 AM - Networking Break
Primary Care Updates
To date, the following organizations have provided educational grants in support of Primary Care Updates: AstraZeneca and This activity is supported by an educational grant from Amgen .
9:15AM
 
9:45AM
 
10:15AM
 
10:45AM
 
11:15AM
 
11:45AM
 
12:15PM
 
9:15 AM-10:45 AM
Managing Hypertension and Obesity through Therapeutics and Lifestyle Modifications
 
 
 
 
 
 
11:00 AM-12:30 PM
New Advancements in Managing the Patient with Severe Dyslipidemia
 
 
 
 
 
Integrated Approaches to Cardiometabolic Care
12:30PM
 
1:00PM
 
1:30PM
 
2:00PM
 
2:30PM
 
3:00PM
 
3:30PM
 
4:00PM
 
4:30PM
 
5:00PM
 
5:30PM
 
6:00PM
 
12:30 PM-2:30 PM
Exploring the Interrelationships of Cardiometabolic Risk and How to Best Manage the Patient Who Presents With Metabolic and Cardiovascular Disease
 
 
 
 
 
 
 
2:30 PM-2:40 PM - Networking Break
2:40 PM-3:40 PM
Managing the Clinical Complexities of Cardiometabolic Disease: What about the Cardiovascular Issues?
 
 
 
 
3:50 PM-4:50 PM
Managing the Clinical Complexities of Cardiometabolic Disease: What about Glucose Control Issues?
 
 
 
4:50 PM-5:00 PM - Networking Break
5:00 PM-5:45 PM
Call to Action: Integrated Approaches to Managing the Complex Cardiometabolic Patient
 
 
5:45 PM-6:30 PM
Faculty & Attendee Networking Reception
 
 
CLOSE  X  
Clarifying the Confusion of COPD: Implementing Guidelines and Good Practice
Room: Room 1, Level 1
Learning Objectives:
  1. Evaluate the benefits of current COPD therapy in improving symptoms and decreasing exacerbations
  2. Utilize current guidelines for the diagnosis of COPD, including the use of spirometry and management of symptoms
  3. Integrate recently approved agents to help prevent and treat COPD exacerbations
Faculty:
  1. Jill Ohar, MD, Professor, Pulmonary, Critical Care, Allergy, and Immunologic Medicine, Center for Genomics and Personalized Medicine Research, Comprehensive Cancer Center, Center for Worker Health, Director for Respiratory Therapy, Wake Forest Baptist HealthWinston-Salem, NC
  2. Fernando Martinez, MD, MS, Professor, Department of Internal Medicine, Director, Pulmonary Diagnostic Services, University of MichiganAnn Arbor, MI
CLOSE  X  
Weighing the Consequences: The Time Is Now for Tackling the Obesity Epidemic
Room: Room 26, Level 2
Learning Objectives:
  1. Identify and evaluate patients with obesity by using parameters such as body mass index, waist circumference, and risk factor assessment
  2. Engage patients in open dialogues, highlighting the importance of lifestyle modification including decreased energy intake and exercise as part of a healthy lifestyle
  3. Confidently utilize pharmacologic agents to reinforce lifestyle change for patients with obesity and obesity-related comorbid conditions
Faculty:
  1. Donna Ryan, MD, Professor Emeritus, Pennington Biomedical Research CenterBaton Rouge, LA (Bio)
  2. Michelle Look, FAAFP, MD, Family Practice-Sports Medicine Physician, San Diego Sports Medicine and Family Health CenterSan Diego, CA
CLOSE  X  
Insulin Replacement Therapy for Type 2 Diabetes: Patient-Centered Management of Hyperglycemia in Primary Care
Room: Room 23, Level 2
Learning Objectives:
  1. Discuss the multisystem consequences of T2DM and the rationale for appropriate screening, early diagnosis, and prompt treatment
  2. Establish individualized treatment goals for patients with T2DM according to disease duration, age, comorbidities, and ongoing evaluations of hemoglobin A1C, blood glucose profiles, and therapeutic responses
  3. Employ evidence-based frameworks and new treatment approaches to individualize basal and mealtime insulin therapies across diverse T2DM patient populations
  4. Integrate patient-specific clinical and psychosocial factors into comprehensive treatment plans that include lifestyle modifications and pharmacologic interventions for T2DM
  5. Educate patients with T2DM about the importance of treatment adherence and the risks of insulin-related hypoglycemia
Faculty:
  1. Jeff Unger, MD, FACE , ABFM, Assistant Professor of Family Medicine, Loma Linda University School of MedicineRiverside, CA, Director, Metabolic Studies, Catalina Research InstituteChino, CA
  2. Glenn Matfin, MD, Clinical Professor of Medicine, University of MinnesotaMinneapolis, MN, Research Clinician, International Diabetes CenterSt Louis, MN
  3. Derek LeRoith, MD, PhD, Professor of Medicine, Director of Research, Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of MedicineNew York, NY
CLOSE  X  
AM Break
CLOSE  X  
AM Break
CLOSE  X  
AM Break
CLOSE  X  
How Well Do You Know Your Disease Prevention Guidelines?
Room: Room 1, Level 1
Learning Objectives:
  1. Apply the latest screening recommendations for breast cancer, colorectal cancer, and genitourinary malignancies in your care of patients
  2. Outline the risks and benefits of daily aspirin therapy for primary prevention of cardiovascular events in a variety of patient populations
Faculty:
  1. M. Susan Burke, MD, FACP, Clinical Assistant Professor, Thomas Jefferson University Medical SchoolPhiladelphia, PA, Senior Advisor, Internal Medicine Clinical Care Center, Lankenau Medical CenterWynnewood, PA (Bio)
CLOSE  X  
Complementary Therapies to Improve Glucose Control in Type 2 Diabetes: Role of GLP-1 Receptor Agonists & Basal Insulin
Room: Room 26, Level 2
Learning Objectives:
  1. Apply strategies to individualized therapy in the treatment of patients with type 2 diabetes
  2. Incorporate appropriate strategies for timely initiation, selection, titration, and self-management of basal insulin in patients with type 2 diabetes
  3. Describe the similarities and differences between individual GLP-1 receptor agonists
  4. Summarize the clinical rationale and evidence for combining GLP-1 receptor agonists with basal insulin so as to address various underlying pathophysiologic components of type 2 diabetes
Faculty:
  1. Dace Trence, MD, FACE, Director, Diabetes Care Center, Professor, Division of Metabolism, Endocrinology and Nutrition, University of Washington Medical CenterSeattle, WA
  2. Sam Dagogo-Jack, MD, FRCP, Professor of Medicine & Director,Division of Endocrinology, Diabetes & Metabolis, A. C. Mullins Chair in Translational Research, Director, General Clinical Research Center, Director, Endocrinology Fellowship Training Program, University of Tennessee Health Science CenterMemphis, TN
CLOSE  X  
Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: Individualized Management in Primary Care
Room: Room 23, Level 2
Learning Objectives:
  1. Describe pathophysiologic mechanisms in BPH-LUTS and relationships to comorbid conditions and therapeutic approaches
  2. Conduct comprehensive assessments of patients with suspected BPH and associated LUTS
  3. Evaluate the mechanisms of action and clinical profiles of a-blockers, 5-ARIs, and PDE5 inhibitors in the treatment of BPH-LUTS with and without ED
  4. Combine pharmacologic and nonpharmacologic interventions for BPH-LUTS based on symptom severity, common comorbidities, risk of disease progression, and patient goals
  5. Monitor treatment efficacy and adherence in patients with BPH-LUTS to guide therapeutic restructuring and optimize patient outcomes
Faculty:
  1. David Staskin, MD, Associate Professor of Urology, Tufts University School of MedicineBoston, MA, Director, Center for Male and Female Pelvic Health Steward, St. Elizabeth's Medical CenterBoston, MA
  2. Matt T Rosenberg, MD, Director and Founder, Mid-Michigan Health CentersJackson, MI, Chief, Department of Family Medicine, Foote Health SystemJackson, MI
  3. Steven Kaplan, MD, E. Darracott Vaughan Jr. Professor of Urology, Chief, Institute for Bladder and Prostate Health, Weill Cornell Medical CollegeNew York, NY, Director, Iris Cantor Men’s Health Center, New York Presbyterian Hospital, Weill Cornell Medical CenterNew York, NY
CLOSE  X  
Case Work: Evaluating GLP-1 Receptor Agonists in Patient-Centered Care for Type 2 Diabetes
Room: Room 1, Level 1
Learning Objectives:
  1. Evaluate and apply current evidence regarding GLP-1 RA efficacy relative to other agents and across diabetes progression
  2. Evaluate and apply current evidence regarding safety of GLP-1 RAs, including recent data on specific label precautions (eg, thyroid cancer, pancreatitis, renal failure) and cardiovascular disease
  3. Evaluate and apply current evidence regarding tolerability and treatment satisfaction with GLP-1 RAs
  4. Evaluate and apply current evidence regarding nonglycemic effects of GLP-1 RAs (eg, effects on weight, blood pressure, lipid levels)
  5. Educate patients on the causes, symptoms, and risks associated with hypoglycemia and implement new models of care to overcome patient and system barriers to therapeutic regimen adherence
Faculty:
  1. Derek LeRoith, MD, PhD, Professor of Medicine, Director of Research, Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of MedicineNew York, NY
  2. Jay Shubrook, DO , FACOFP , FAAFP, Associate Professor of Family Medicine, Director of Clinical Research, Department of Family Medicine, Director of Diabetes Fellowship, The Diabetes Institute, Ohio University Heritage College of Osteopathic MedicineAthens, OH
CLOSE  X  
Reducing Risk in the Acute Coronary Syndrome Patient: Insights for Primary Care Clinicians
Room: Room 26, Level 2
Learning Objectives:
  1. Describe fundamental pharmacokinetics, pharmacodynamics, and pharmacogenetics of oral antiplatelet therapies
  2. Discuss efficacy and safety data with oral antiplatelet therapies from ACS outcomes trials
  3. Identify therapies to reduce risk and recognize goals to achieve in the management of patients who have experienced an acute coronary syndrome
Faculty:
  1. Marc Sabatine, MD, MPH, Associate Professor of Medicine, Chairman TIMI Study Group, Harvard Medical SchoolBoston, MA
  2. Jeffrey Berger, MD, MS
CLOSE  X  
Weighing the Consequences: The Time Is Now for Tackling the Obesity Epidemic
Room: Room 23, Level 2
Learning Objectives:
  1. Identify and evaluate patients with obesity by using parameters such as body mass index, waist circumference, and risk factor assessment
  2. Engage patients in open dialogues, highlighting the importance of lifestyle modification including decreased energy intake and exercise as part of a healthy lifestyle
  3. Confidently utilize pharmacologic agents to reinforce lifestyle change for patients with obesity and obesity-related comorbid conditions
Faculty:
  1. Donna Ryan, MD, Professor Emeritus, Pennington Biomedical Research CenterBaton Rouge, LA (Bio)
  2. W. Timothy Garvey, MD, Butterworth Professor and Chair, Department of Nutrition Sciences, Director, UAB Diabetes Research & Training Center, University of Alabama at BirminghamBirmingham, AL (Bio)
CLOSE  X  
Lunch
CLOSE  X  
Lunch
CLOSE  X  
Lunch
CLOSE  X  
Weighing the Consequences: The Time Is Now for Tackling the Obesity Epidemic
Room: Room 1, Level 1
Learning Objectives:
  1. Identify and evaluate patients with obesity by using parameters such as body mass index, waist circumference, and risk factor assessment
  2. Engage patients in open dialogues, highlighting the importance of lifestyle modification including decreased energy intake and exercise as part of a healthy lifestyle
  3. Confidently utilize pharmacologic agents to reinforce lifestyle change for patients with obesity and obesity-related comorbid conditions
Faculty:
  1. Michelle Look, FAAFP, MD, Family Practice-Sports Medicine Physician, San Diego Sports Medicine and Family Health CenterSan Diego, CA
  2. Timothy Church, MD, MPH, PhD, Professor and Director, Laboratory of Preventive Medicine, Pennington Biomedical Research CenterBaton Rouge, LA (Bio)
CLOSE  X  
Concussion 2013: An Update
Room: Room 23, Level 2
Learning Objectives:
  1. Differentiate concussion presentation from other forms of traumatic brain injury
  2. Implement the latest guidelines for managing the concussion patient including recommendations for returning back to work or sports
Faculty:
  1. Adam Chrusch, MD, Adjunct Assistant Clinical Professor of Family and Community Medicine, Drexel University College of MedicinePhiladelphia, PA, Adjunct Assistant Clinical Professor of Family and Community Medicine, Temple University School of MedicinePhiladelphia, PA, Assistant Program Director, Family Medicine Residency Program, Abington Memorial Hospital Abington, PA (Bio)
CLOSE  X  
Testosterone Replacement Therapy: Controversies and Answers
Room: Room 26, Level 2
Learning Objectives:
  1. Identify the signs and symptoms of hypogonadism and their clinical presentation
  2. Identify the role of hypogonadism in diabetes, obesity, metabolic syndrome, and cardiovascular disease
  3. Select options available to effectively treat hypogonadism
  4. Implement monitoring strategies for patients on TRT
Faculty:
  1. Andre Guay, MD, FACP , FACE, Director, Center for Sexual Function/Endocrinology, Lahey Clinic, North ShorePeabody, MA, Clinical Professor of Medicine, Tufts University School of MedicineBoston, MA
  2. Martin Miner, MD, Chief of Primary Care and Community Medicine, Co-Director, Men's Health Center, The Miriam HospitalProvidence, RI, Clinical Associate Professor, Family Medicine and Urology, The Warren Alpert Medical School, Brown University Providence, RI (Bio)
CLOSE  X  
PM Break
CLOSE  X  
PM Break
CLOSE  X  
Depression: When Medical and Psychiatric Factors Collide
Room: Room 1, Level 1
Learning Objectives:
  1. Identify the relationship between depression and medical factors (inflammatory, endocrine, metabolic)
  2. Select optimal treatments for patients with depression and comorbid medical conditions
  3. Assess the potential utility of biomarkers in the diagnosis and treatment of depression
Faculty:
  1. Andrew Cutler, MD, Courtesy Assistant Professor, Department of Psychiatry, University of FloridaGainesville, FL, CEO & Chief Medical Officer, Florida Clinical Research Center, LLCMaitland, FL (Bio)
CLOSE  X  
PM Break
CLOSE  X  
Tackling the Toughest Issues and Cases of Hypertriglyceridemia
Room: Room 23, Level 2
Learning Objectives:
  1. Discuss the role of elevated triglyceride levels in the assessment and diagnosis of dyslipidemia, including cardiovascular risk factors
  2. Apply best practices in the attainment of TG levels, including the role of fasting and nonfasting states in accurate evaluation
  3. Evaluate the management of hypertriglyceridemia through greater adherence to evidence-based practices and accepted guidelines
  4. Select potential new and emerging therapeutic approaches to manage TG-based dyslipidemia, mixed dyslipidemia, and associated cardiovascular risk
Faculty:
  1. JoAnne Foody, MD, FACC, FAHA, Medical Director, Pollin Cardiovascular Wellness Program, Brigham and Women's HospitalBoston, MA, Associate Professor of Medicine, Harvard Medical SchoolBoston, MA (Bio)
  2. Karol Watson, MD, PhD, FACC, Director, UCLA Women's Cardiovascular Center, UCLA Los Angeles, CA, Co-Director, UCLA Cholesterol, Hypertension, and Atherosclerosis Management Program (CHAMP), UCLA Los Angeles, CA, Co-Director, UCLA Program in Preventative Cardiology, Professor of Medicine, UCLA Cardiology, UCLA Los Angeles, CA (Bio)
CLOSE  X  
Incretin-Based Therapies for Type 2 Diabetes: Mechanism-Based Strategies to Achieve Patient-Centered Care
Room: Room 26, Level 2
Learning Objectives:
  1. Discuss the multisystem causes and consequences of T2DM, including pathologic roles of the incretin pathways and rationale for early diagnosis
  2. Individualize treatment goals for patients with T2DM based on disease duration, age, relevant comorbidities, and ongoing evaluations of hemoglobin A1C levels and therapeutic responses
  3. Evaluate the mechanisms of action and clinical profiles of incretin-based therapies, including GLP-1 agonists and DPP-4 inhibitors
  4. Develop and tailor personalized multimodal treatment plans for T2DM that include lifestyle interventions and incretin-based therapies alone or in combination with other antihyperglycemic medications
  5. Educate diverse patient populations with T2DM about lifestyle modifications, benefits and risks of various antihyperglycemic medications, and the importance of treatment adherence
Faculty:
  1. Javier Morales, MD, Vice President, Principal Clinical Trails Investigator, Advanced Internal Medicine GroupNew Hyde Park, NY (Bio)
  2. Lawrence Blonde, MD, FACP, FACE, Director of the Ochsner Diabetes Clinical Research Unit, Associate Internal Medicine Residency Program Direct, Ochsner Medical CenterNew Orleans, LA (Bio)
  3. Jack Leahy, MD, Chief, Division of Endocrinology, Diabetes and Metabolism, University of VermontBurlington, VT (Bio)
Primary Care Updates Track 1
To date, the following organizations have provided educational grants in support of Primary Care Updates Track 1: Forest Laboratories, Novo Nordisk Inc., Vivus and PamLab.
Primary Care Updates Track 2
To date, the following organizations have provided educational grants in support of Primary Care Updates Track 2: Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com, Vivus and Amarin Corporation plc.
Primary Care Updates Track 3
To date, the following organizations have provided educational grants in support of Primary Care Updates Track 3: Vivus, sanofi-aventis U.S. Inc., AstraZeneca, Abbvie, Lilly, For further information concerning Lilly grant funding visit www.lillygrantoffice.com and Bristol-Myers Squibb and AstraZeneca LP.
7:45AM
 
8:15AM
 
8:45AM
 
9:15AM
 
9:45AM
 
10:15AM
 
10:45AM
 
11:15AM
 
11:45AM
 
12:15PM
 
12:45PM
 
1:15PM
 
1:45PM
 
2:15PM
 
2:45PM
 
3:15PM
 
3:45PM
 
7:45 AM-9:00 AM
Clarifying the Confusion of COPD: Implementing Guidelines and Good Practice
7:45 AM-9:15 AM
Insulin Replacement Therapy for Type 2 Diabetes: Patient-Centered Management of Hyperglycemia in Primary Care
7:45 AM-9:00 AM
Weighing the Consequences: The Time Is Now for Tackling the Obesity Epidemic
   
   
   
   
9:00 AM-9:15 AM - AM Break
 
9:00 AM-9:15 AM - AM Break
9:15 AM-10:30 AM
How Well Do You Know Your Disease Prevention Guidelines?
9:15 AM-9:30 AM - AM Break
9:15 AM-10:45 AM
Complementary Therapies to Improve Glucose Control in Type 2 Diabetes: Role of GLP-1 Receptor Agonists & Basal Insulin
 
9:30 AM-11:00 AM
Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: Individualized Management in Primary Care
 
   
   
   
10:30 AM-12:00 PM
Case Work: Evaluating GLP-1 Receptor Agonists in Patient-Centered Care for Type 2 Diabetes
  
  
10:45 AM-12:15 PM
Reducing Risk in the Acute Coronary Syndrome Patient: Insights for Primary Care Clinicians
 
11:00 AM-12:15 PM
Weighing the Consequences: The Time Is Now for Tackling the Obesity Epidemic
 
   
   
   
12:00 PM-12:45 PM - Lunch
  
 
12:15 PM-1:00 PM - Lunch
12:15 PM-1:00 PM - Lunch
   
12:45 PM-2:00 PM
Weighing the Consequences: The Time Is Now for Tackling the Obesity Epidemic
  
 
1:00 PM-2:15 PM
Concussion 2013: An Update
1:00 PM-2:15 PM
Testosterone Replacement Therapy: Controversies and Answers
   
   
   
2:00 PM-2:15 PM - PM Break
  
2:15 PM-3:30 PM
Depression: When Medical and Psychiatric Factors Collide
2:15 PM-2:30 PM - PM Break
2:15 PM-2:30 PM - PM Break
 
2:30 PM-3:45 PM
Tackling the Toughest Issues and Cases of Hypertriglyceridemia
2:30 PM-4:00 PM
Incretin-Based Therapies for Type 2 Diabetes: Mechanism-Based Strategies to Achieve Patient-Centered Care
   
   
   
   
   
CLOSE  X  
Registration and Breakfast
CLOSE  X  
Welcome and Opening Remarks
Room: Hall A, Level 1
CLOSE  X  
Obesity in America from the Dietary Counselor and Lifestyle Coach from "The Biggest Loser"
Room: Hall A, Level 1
Getting your patients to lose weight is never easy. Learn in this keynote adress from the weight loss and nutirition consultant to NBC's "The Biggest Loser" about effective lifestyle and behavioral approaches to achieve weight loss goals in your overweight and obese patients.
Learning Objectives:
  1. Employ proven, evidence-based lifestyle and behavioral modalities to help your obese patients lose weight and achieve health benefits.
Faculty:
  1. Michael Dansinger, MD (Bio)
CLOSE  X  
Networking Break and Additional Opportunities
CLOSE  X  
Targeting Better Cardiac Outcomes for High-Risk Patients
Room: Room 23, Level 2
This session will provide important update information on low HDL-C levels and elevated triglycerides as therapeutic targets to reduce cardiovascular disease risk.
Learning Objectives:
  1. Evaluate recent clinical trials with respect to management of low HDL
  2. Examine the data on triglycerides and CVD risk to determine how aggressively to treat patients with elevated TGs
  3. Employ strategies for reducing CVD risk in patients with type 2 diabetes and hypertension
Faculty:
  1. Danielle Duffy, FACC, MD, Assistant Professor of Medicine, Division of Cardiology, Jefferson Medical CollegePhiladelphia, PA, Director, Cardiovascular Risk Reduction, Jefferson Heart InstitutePhiladelphia, PA (Bio)
CLOSE  X  
Live Demonstration Orthopedic Exam: See It, Do it
Room: Hall A, Level 1
Learn orthopedic maneuvers to assess common office-based musculoskeletal complaints.
Learning Objectives:
  1. Improve your ability to diagnose common musculoskeletal complaints including upper body, low back, hip, and knee
Faculty:
  1. Christopher Smith, MD, FACP, Associate Proessor of Medicine, Harvard Medical SchoolBoston, MA, Associate Director, Internal Medicine Residency Program, Co-Director, Rabkin Fellowship in Medical Education, Beth Israel Deaconess Medical CenterBoston, MA (Bio)
CLOSE  X  
Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis
Room: Room 23, Level 2
This session will provide new insight into the pathogenesis of dyslipidemia in the type 2 diabetic patient with chronic kidney disease and the rationale for advanced lipid testing (i.e., lipoprotein particle analysis) in these patient at high CV risk.
Learning Objectives:
  1. Describe the pathogenesis of dyslipidemias in patients with diabetes and chronic kidney disease.
  2. Understand the rationale for performing lipoprotein particle analysis in patients with high CV risk comorbidities.
Faculty:
  1. Matthew Sorrentino, FASH , MD, FACC, Professor of Medicine, Department of Medicine, Section of Cardiology, University of Chicago Pritzker School of MedicineChicago, IL (Bio)
CLOSE  X  
Lunch and Additional Opportunities
CLOSE  X  
SAFE Opioid Prescribing: Evaluation is Essential for Safe and Effective Pain Management Using ER/LA Opioids
Room: Hall A, Level 1
Complete all 6 sessions and you will receive REMS compliant training certificate. This activity is intended to be fully-compliant with the ER/LA Opioid Analgesics REMS education requirements issued by the U.S. Food & Drug Administration (FDA). This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies (RPC). Please see www.er-la-opioidREMS.com for a listing of the member companies.
Learning Objectives:
  1. Identify risk factors for opioid-related aberrant behavior
  2. Differentiate between tolerance, physical dependence and addiction
Faculty:
  1. Charles Argoff, MD
  2. Steven Stanos, DO (Bio)
  3. Bill McCarberg, MD (Bio)
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies (RPC). Please see www.er-la-opioidREMS.com for a listing of the member companies. This activity is intended to be fully-compliant with the ER/LA Opioid Analgesics REMS education requirements issued by the U.S. Food & Drug Administration (FDA).
CLOSE  X  
Improve Patient Outcomes with Effective Diagnosis and Treatment of Underlying Psychiatric Disorders
Room: Room 23, Level 2
Improve your recognition of the signs and symptoms of major depressive disorder with differentiation from bipolar disorder. Improve your knowledge in the best practice selection of pharmacologic treatments for patients with uncomplicated depression and somatization.
Learning Objectives:
  1. Recognize the signs and symptoms of major depressive disorder and initiate therapy with close monitoring
  2. Differentiate bipolar disease from symptoms of depression in order to determine appropriate treatment
  3. Consider actions and side effects of drugs and drug classes when deciding on which treatment to select for specific patients with psychiatric disorders
Faculty:
  1. Rosalind Kaplan, FACP, MD, Associate Professor of Clinical Medicine, Temple University School of MedicinePhiladelphia, PA, Director, Temple Health Women's Care, Temple University School of MedicinePhiladelphia, PA (Bio)
CLOSE  X  
SAFE Opioid Prescribing: Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between
Room: Hall A, Level 1
Improve your ability to adjust treatment when converting from immediate release opioid formulations to extended release/long-acting preparations, as well as your ability to identify risk factors for opioid-induced respiratory depression.
Learning Objectives:
  1. Convert patients from immediate-release to ER/LA opioids as well as from one ER/LA opioid to another
  2. Identify predisposing risk factors for significant respiratory depression
Faculty:
  1. Charles Argoff, MD
  2. Steven Stanos, DO, Assistant Professor, Department of Physical Medicine and Rehabilitation, Assistant Program Director, Multidisciplinary Pain Fellowship, Northwestern University Feinberg School of MedicineChicago, IL, Medical Director, Center for Pain Management, Rehabilitation Institute of ChicagoChicago, IL (Bio)
  3. Bill McCarberg, MD (Bio)
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies (RPC). Please see www.er-la-opioidREMS.com for a listing of the member companies. This activity is intended to be fully-compliant with the ER/LA Opioid Analgesics REMS education requirements issued by the U.S. Food & Drug Administration (FDA).
CLOSE  X  
Tips for Managing Behavioral Issues in Elderly Patients with Dementia
Room: Room 23, Level 2
Elderly patients with dementia present the practicing physician with the challenge of managing the psychiatric and behavioral spectrum of this disorder: memory problems, mood disorders, sleep distrubances, apathy,delutions, hallucinations, wandering, and agitation . This session will provide assistance in the differential diagnosis and the selection of appropriate pharmacologic and nonpharmacologic treatments for behavioral problems.
Learning Objectives:
  1. Differentiate the variation in symptoms of the dementing disorders depending upon their etiology
  2. Apply appropriate pharmacologic therapies for behavioral problems associated with dementia
  3. Apply appropriate non-pharmacological therapies for agitation, with special attention to the environment
Faculty:
  1. Katherine Galluzzi, DO, CMD, Professor and Chairperson, Department of Geriatric Medicine, Department of Geriatric MedicinePhiladelphia, PA, Director, Comprehensive Care @ PCOM, Philadelphia College of Osteopathic MedicinePhiladelphia, PA, Medical Director, Hospice of Philadelphia, VNA of Greater PhiladelphiaPhiladelphia, PA (Bio)
CLOSE  X  
SAFE Opioid Prescribing: Evidence-Based Tools for Screening for Patients at Risk and Monitoring for Adherence to Prescribed ER/LA Opioids
Room: Hall A, Level 1
Improve your ability to manage adverse reactions with extended release/long-acting opioid formulations and to monitor patient adherence to treatment.
Learning Objectives:
  1. Evaluate and manage adverse effects of ER/LA-opioids
  2. Differentiate strategies for monitoring patient adherence
Faculty:
  1. Charles Argoff, MD, Professor of Neurology, Albany Medical College, Director, Comprehensive Pain Center, Albany Medical Center Albany, NY, Professor of Neurology, Albany Medical College, Director, Comprehensive Pain Center, Albany Medical Center Albany, NY
  2. Steven Stanos, DO (Bio)
  3. Bill McCarberg, MD (Bio)
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies (RPC). Please see www.er-la-opioidREMS.com for a listing of the member companies. This activity is intended to be fully-compliant with the ER/LA Opioid Analgesics REMS education requirements issued by the U.S. Food & Drug Administration (FDA).
CLOSE  X  
SAFE Opioid Prescribing: Talk to Me: Proven Methods to Counsel Your Patients on ER/LA Opioids and Achieve Positive Outcomes
Room: Hall A, Level 1
This session will provide important take away strategies for counseling patients and caregivers to ensure appropriate use of extended release/long-acting opioids and recognition of signs of overdose.
Learning Objectives:
  1. Implement counseling strategies to ensure patients know to take ER/LA opioids exactly as prescribed
  2. Use counseling strategies to explain signs of ER/LA opioid overdose to patients and caregivers
Faculty:
  1. Charles Argoff, MD
  2. Steven Stanos, DO, Assistant Professor, Department of Physical Medicine and Rehabilitation, Assistant Program Director, Multidisciplinary Pain Fellowship, Northwestern University Feinberg School of MedicineChicago, IL, Medical Director, Center for Pain Management, Rehabilitation Institute of ChicagoChicago, IL (Bio)
  3. Bill McCarberg, MD (Bio)
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies (RPC). Please see www.er-la-opioidREMS.com for a listing of the member companies. This activity is intended to be fully-compliant with the ER/LA Opioid Analgesics REMS education requirements issued by the U.S. Food & Drug Administration (FDA).
CLOSE  X  
Networking Break
CLOSE  X  
Management of the Long-Term Effects of Cancer and Cancer Therapy in Primary Care
Room: Room 23, Level 2
Cardiovascular health is increasingly becoming an issue in long-term cancer survivors, requiring closer attention to its management. Learn how to assess and address cardiovascular risk in cancer survivors.
Learning Objectives:
  1. Explore the evidence regarding cardiovascular disease in survivors of certain types of cancer
  2. Encourage cancer survivor patients to adopt healthy lifestyles to reduce CV and cancer risk
  3. Implement screening guidelines for cancer survivors to reduce future cancer risk
Faculty:
  1. Kevin Oeffinger, MD, Dir., Living Beyond Cancer: A Program for Adult Survivors of Pediatric Cancer, Departments of Pediatrics and Internal Medicine, Memorial Sloan-Kettering Cancer CenterNew York, NY (Bio)
CLOSE  X  
SAFE Opioid Prescribing: Everything You Always Wanted to Know About ER/LA-Opioids as a Drug Class
Room: Hall A, Level 1
When individualizing your pain management treatment approach, learn how to assess differences in opioid metabolism and potential drug interactions in your patient, and how these factors will impact treatment.
Learning Objectives:
  1. Assess the differences in opioid metabolism and how these impact appropriate ER/LA prescribing
  2. Identify how opioid-drug interactions influence ER/LA opioid prescribing
Faculty:
  1. Charles Argoff, MD
  2. Steven Stanos, DO (Bio)
  3. Bill McCarberg, MD (Bio)
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies (RPC). Please see www.er-la-opioidREMS.com for a listing of the member companies. This activity is intended to be fully-compliant with the ER/LA Opioid Analgesics REMS education requirements issued by the U.S. Food & Drug Administration (FDA).
CLOSE  X  
SAFE Opioid Prescribing: Getting the Most Clinical Insights from Specific ER/LA Product Information Sources
Room: Hall A, Level 1
Improve your understanding of the official prescribing information for available extended release/long-acting opioids, as well as the doses indicated for opioid-tolerant patients
Learning Objectives:
  1. Differentiate the prescribing information among available ER/LA opioids
  2. Identify ER/LA opioids and dosages indicated for opioid-tolerant patients only
Faculty:
  1. Charles Argoff, MD
  2. Steven Stanos, DO (Bio)
  3. Bill McCarberg, MD (Bio)
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies (RPC). Please see www.er-la-opioidREMS.com for a listing of the member companies. This activity is intended to be fully-compliant with the ER/LA Opioid Analgesics REMS education requirements issued by the U.S. Food & Drug Administration (FDA).
CLOSE  X  
Screening for Colorectal Cancer: There is No "Best" Screening Test
Room: Room 23, Level 2
A thorough review of colorectal cancer screening tests. Is colonoscopy for all is the best approach?
Learning Objectives:
  1. Describe the advantages and disadvantages of the available screening tests for colorectal cancer
  2. Assess the evidence supporting use of the available screening tests for colorectal cancer
Faculty:
  1. James Allison, MD , FACP , AGAF, Clinical Professor of Medicine Emeritus, University of California, San FranciscoSan Francisco, CA, Adjunct Investigator, Division of Research, KaiserS San Fran, CA (Bio)
CLOSE  X  
Medical Brain Game: SAFE Opioid Prescribing Edition
Room: Hall A, Level 1
This session makes use of an engaging quiz show format to reinforce the essential elements in the appropriate use of opioids in pain management.
Learning Objectives:
  1. Compete in this practical, REMS-themed medical knowledge game, sure to provide a fun challenge
Faculty:
  1. Charles Argoff, MD
  2. Steven Stanos, DO (Bio)
  3. Bill McCarberg, MD (Bio)
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies (RPC). Please see www.er-la-opioidREMS.com for a listing of the member companies. This activity is intended to be fully-compliant with the ER/LA Opioid Analgesics REMS education requirements issued by the U.S. Food & Drug Administration (FDA).
 
 SAFE Opioid Prescribing | Strategies. Assessment. Fundamentals. Education.
6:30AM
 
7:00AM
 
7:30AM
 
8:00AM
 
8:30AM
 
9:00AM
 
9:30AM
 
10:00AM
 
10:30AM
 
11:00AM
 
11:30AM
 
12:00PM
 
12:30PM
 
1:00PM
 
1:30PM
 
2:00PM
 
2:30PM
 
3:00PM
 
3:30PM
 
4:00PM
 
4:30PM
 
5:00PM
 
5:30PM
 
6:30 AM-7:30 AM - Registration and Breakfast
 
 
 
7:30 AM-7:45 AM - Welcome and Opening Remarks
7:45 AM-8:45 AM
Obesity in America from the Dietary Counselor and Lifestyle Coach from "The Biggest Loser"
 
 
 
8:45 AM-9:30 AM - Networking Break and Additional Opportunities
 
 
9:30 AM-11:30 AM
Live Demonstration Orthopedic Exam: See It, Do it
9:30 AM-10:30 AM
Targeting Better Cardiac Outcomes for High-Risk Patients
 
 
 
10:30 AM-11:30 AM
Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis
 
 
 
11:30 AM-1:30 PM - Lunch and Additional Opportunities
 
 
 
 
 
 
 
1:30 PM-2:00 PM
SAFE Opioid Prescribing: Evaluation is Essential for Safe and Effective Pain Management Using ER/LA Opioids
1:30 PM-2:30 PM
Improve Patient Outcomes with Effective Diagnosis and Treatment of Underlying Psychiatric Disorders
 
2:00 PM-2:30 PM
SAFE Opioid Prescribing: Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between
 
2:30 PM-3:00 PM
SAFE Opioid Prescribing: Evidence-Based Tools for Screening for Patients at Risk and Monitoring for Adherence to Prescribed ER/LA Opioids
2:30 PM-3:30 PM
Tips for Managing Behavioral Issues in Elderly Patients with Dementia
 
3:00 PM-3:30 PM
SAFE Opioid Prescribing: Talk to Me: Proven Methods to Counsel Your Patients on ER/LA Opioids and Achieve Positive Outcomes
 
3:30 PM-3:45 PM - Networking Break
3:45 PM-4:15 PM
SAFE Opioid Prescribing: Everything You Always Wanted to Know About ER/LA-Opioids as a Drug Class
3:45 PM-4:45 PM
Management of the Long-Term Effects of Cancer and Cancer Therapy in Primary Care
 
4:15 PM-5:00 PM
SAFE Opioid Prescribing: Getting the Most Clinical Insights from Specific ER/LA Product Information Sources
 
4:45 PM-5:45 PM
Screening for Colorectal Cancer: There is No "Best" Screening Test
5:00 PM-5:45 PM
Medical Brain Game: SAFE Opioid Prescribing Edition
 
 
CLOSE  X  
Registration and Breakfast
CLOSE  X  
Welcome and Opening Remarks
Room: Hall A, Level 1
CLOSE  X  
In Search of Joy in Practice: Innovations in Patient Centered Care
Room: Hall A, Level 1
Attend this session to learn about innovations that you can use right now in your practice to improve your own satisfaction in your practice and advance the quality of the care you provide to your patients.
Learning Objectives:
  1. Identify 3 innovations to improve quality and satisfaction of practice
  2. Integrate cost-effective innovations into your practice
Faculty:
  1. Christine Sinsky, MD, General Internist, Medical Associates Clinic and Health PlansDubuque, IA
  2. Thomas Sinsky, MD, General Internist, Medical Associates Clinic and Health PlansDubuque, IA
CLOSE  X  
Networking Break and Additional Opportunities
CLOSE  X  
Obstructive Sleep Apnea: Interventions That Will Help Your Patients Sleep Better
Room: Hall A, Level 1
This session will provide guidance on whom to screen for obstructive sleep apnea in your primary care practice, how to screen, interventions and the differences you will encounter between male and female patients with this condition.
Learning Objectives:
  1. Implement practice-based procedures to screen and manage patients at risk for or with evidence of obstructive sleep apnea
  2. Co-manage patients with OSA and encourage continued monitoring and compliance with CPAP therapy
Faculty:
  1. Jonathan Lown, MD, Adjunct Faculty, Stony Brook UniversityStony Brook, NY (Bio)
CLOSE  X  
Engaging e-Patients: How e-Messaging, Personal Health Records, and Patient Activation Can Transform Your Practice
Room: Room 23, Level 2
Participatory medicine is being driven by e-health technoloogy and represents a significant paradigm shift. Learn how e-messaging, patient health records/patient portals and online resources can and are improving patient care through improved communication between you and your patients.
Learning Objectives:
  1. Take advantage of online resources to expand your medical knowledge and augment your clinical expertise
  2. Provide practical advice to patients about smart and appropriate use of web-based health information and social media
Faculty:
  1. Daniel Sands, MD, MPH, Assistant Clinical Professor of Medicine, Harvard Medical SchoolBoston, MA, Attending Physician, Beth Israel Deaconess Medical CenterBoston, MA (Bio)
CLOSE  X  
VTE Prevention: Avoiding the Avoidable in Medical and High-Risk Patients
Room: Hall A, Level 1
Venous thromboembolism (VTE) is a disease that includes both deep vein thrombosis and pulmonary embolism. This session will assist you in identifying high risk medical and hospitalized patients in whom thromboprophylaxis should be initiated and appropriate oral regimens for extended thromboprophylaxis after hospital discharge.
Learning Objectives:
  1. Identify high risk medical and hospitalized patients for whom thromboprophylaxis should be initiated
  2. Determine appropriate oral regimens for extended thromboprophylaxis after hospital discharge
Faculty:
  1. Matthew Rondina, MD (Bio)
CLOSE  X  
Maximizing Efficiency: People, Process, and Information Technology Tools for Your Practice
Room: Room 23, Level 2
Beyond the CMS meaningful use requirements, learn how the use of EHR systems can improve all aspects of your practice through access to and use of health information.
Learning Objectives:
  1. Learn about the time-saving and patient-specific applications of the electronic health record that can improve efficiency and the quality of patient care
Faculty:
  1. Michael Zaroukian, MD
CLOSE  X  
Lunch and Additional Opportunities
CLOSE  X  
The Problem Pests: Ticks, Mites, Bed Bugs, and Lice
Room: Room 23, Level 2
This session will provide you with actionable information regarding insect pest borne infectious diseases, including the topic of the manifestations of Lyme disease and test interpretation to manage these patients and identifying body lice infestation with patient education regarding treatment and prevention.
Learning Objectives:
  1. Consider the manifestations of Lyme disease and testing interpretation in order to appropriately manage patients with suspected infection
  2. Identify body lice and educate patients and families about treatment and infestation prevention
Faculty:
  1. Stephen Gluckman, MD, Professor of Medicine, Perelman School of Medicine, University of PennsylvaniaPhiladelphia, PA, Medical Director, Penn Global MedicinePhiladelphia, PA (Bio)
CLOSE  X  
Test Your Skills in Difficult Cases: Nephrology, Hypertension, and Atrial Fibrillation
Room: Hall A, Level 1
Nephrology cases can be challenging. Gain an understanding of how best to manage complex cases with (or sometimes without) a nephrologist. Early recognition of kidney disease and subsequent referral may make a great difference in long term patient and renal outcomes. This session will provide important take away information on the use of anticoagulant therapy in afib patients that is evidence and guideline based. Also included will be approaches to differentiate between rate and rhythm control that can direct appropriate treatment strategies.
Learning Objectives:
  1. Consider and explore renal causes for resistent hypertension or edema
  2. Recognize when prompt referral is indicated for patients with rapidly progressing renal disease
  3. Describe current guidelines and clinical evidence regarding the use of anticoagulant therapy in patients with atrial fibrillation.
  4. Differentiate between rate and rhythm control in atrial fibrillation and direct appropriate treatment strategies based on these parameters.
Faculty:
  1. LaTonya Hickson, MD, FASN
  2. Kent Nilsson, MD, FACC, Assistant Professor of Medicine, Director, Complex Ablations, Athens Regional Medical Center, University of Georgia/Georgia Regents UniversityAthens, GA (Bio)
CLOSE  X  
Infectious Diseases Update in Primary Care
Room: Room 23, Level 2
This infectious disease update session provides guidance on applying current clinical guidelines to the diagnosis and treatment of acute bacterial sinusitis, differential diagnosis and management of latent tuberculosis infection, and evidence-based management of genital herpes.
Learning Objectives:
  1. Apply current clinical guidelines to the diagnosis and treatment of acute bacterial sinusitis
  2. Differentiate the diagnosis of latent tuberculosis infection from that of active tuberculosis
  3. Apply current evidence and guidelines to the clinical management of genital herpes
Faculty:
  1. Neil Skolnik, MD, Professor, Family and Community Medicine, Temple University School of MedicinePhiladelphia, PA, Associate Director, Family Medicine Residency Program, Abington Memorial HospitalAbington, PA (Bio)
CLOSE  X  
Networking Break
CLOSE  X  
Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic
Room: Room 23, Level 2
Non-alcoholic fatty liver disease is seen in many patients who are overweight or obese, or have diabetes, high cholesterol or high triglycerides. This session will review the spectrum of this condition, risk factors, referral advice, and application of the most current evidence-based recommendations for management.
Learning Objectives:
  1. Identify the risk factors and disease spectrum of non-alcoholic fatty liver disease
  2. Apply the latest evidence-based recommendations for the management of NAFLD
  3. Understand the indications for liver biopsy and further investigation
Faculty:
  1. Naga Chalasani, MD, David W. Crabb, Professor and Director, Division of Gastroenterology and Hepatology, Indiana University School of MedicineIndianapolis, IN (Bio)
CLOSE  X  
Lipid Management: A Primary Care Perspective
Room: Hall A, Level 1
Be up to date on current studies evaluating the benefits of raising HDL in reducing CV risk and how intense treatment should be to reduce residual risk for CHD.
Learning Objectives:
  1. Evaluate the latest outcomes findings on raising HDL via pharmacotherapy
  2. Examine the research that focuses on goals other than LDL lowering to reduce CV risk in patients with multiple risk factors
  3. Consider more aggressive strategies for reducing "residual risk" in patients significant CV comorbidities in addition to dyslipidemia
Faculty:
  1. Alan Brown, MD, FACC, FNLA , FAHA, Director, Division of Cardiology, Advocate Lutheran General HospitalPark Ridge, IL (Bio)
CLOSE  X  
New Insights into Reducing Cardiovascular Risk in Patients with Type 2 Diabetes
Room: Hall A, Level 1
This session will provide actionable information for implementing current evidence-based guidelines to reduce CVD risk in type 2 diabetes patients and will utilize a case-based approach that addresses CV risk factors such a dyslipidemia and hypertension in these patients.
Learning Objectives:
  1. Implement current evidence-based guidelines to reduce the risk of CVD in patients with type 2 diabetes mellitus.
  2. Utilize a case-based approach to address the management of CV risk factors (e.g., dyslipidemia, hypertension) in the type 2 diabetes patient.
Faculty:
  1. Michael Bloch, MD, FACP, FASH, Associate Professor, Department of Internal Medicine, University of Nevada School of MedicineReno, NV, Medical Director, Vascular Medicine and Anticoagulation Services, Renown Heart and Vascular InstituteReno, NV (Bio)
CLOSE  X  
Fighting a Growing Epidemic: A Viral Hepatitis Update
Room: Room 23, Level 2
This session will provide up-to-date guidelines for screening and evaluating patients with HCV virus infection in the primary care setting. Current best evidence will be presented to guide initiation of antiviral therapy and treatment monitoring for HCV and HBV.
Learning Objectives:
  1. Assess updated guidelines for screening and evaluating patients for HCV in the primary care setting
  2. Direct antiviral therapy for HCV and HBV using best available evidence
  3. Monitor patients for antiviral treatment response and toxicities
Faculty:
  1. Nancy Reau, MD, Associate Professor of Medicine, Medicine, University of Chicago Chicago, IL (Bio)
 
 EHR in Primary Practice | Tools, Tips and Cases to Maximize Usability in Your Office
6:30AM
 
7:00AM
 
7:30AM
 
8:00AM
 
8:30AM
 
9:00AM
 
9:30AM
 
10:00AM
 
10:30AM
 
11:00AM
 
11:30AM
 
12:00PM
 
12:30PM
 
1:00PM
 
1:30PM
 
2:00PM
 
2:30PM
 
3:00PM
 
3:30PM
 
4:00PM
 
4:30PM
 
5:00PM
 
5:30PM
 
6:30 AM-7:30 AM - Registration and Breakfast
 
 
 
7:30 AM-7:45 AM - Welcome and Opening Remarks
7:45 AM-8:45 AM
In Search of Joy in Practice: Innovations in Patient Centered Care
 
 
 
8:45 AM-9:30 AM - Networking Break and Additional Opportunities
 
 
9:30 AM-10:30 AM
Obstructive Sleep Apnea: Interventions That Will Help Your Patients Sleep Better
9:30 AM-10:30 AM
Engaging e-Patients: How e-Messaging, Personal Health Records, and Patient Activation Can Transform Your Practice
 
 
 
10:30 AM-11:30 AM
VTE Prevention: Avoiding the Avoidable in Medical and High-Risk Patients
10:30 AM-11:30 AM
Maximizing Efficiency: People, Process, and Information Technology Tools for Your Practice
 
 
 
11:30 AM-1:30 PM - Lunch and Additional Opportunities
 
 
 
 
 
 
 
1:30 PM-3:30 PM
Test Your Skills in Difficult Cases: Nephrology, Hypertension, and Atrial Fibrillation
1:30 PM-2:30 PM
The Problem Pests: Ticks, Mites, Bed Bugs, and Lice
 
 
 
2:30 PM-3:30 PM
Infectious Diseases Update in Primary Care
 
 
 
3:30 PM-3:45 PM - Networking Break
3:45 PM-4:45 PM
Lipid Management: A Primary Care Perspective
3:45 PM-4:45 PM
Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic
 
 
 
4:45 PM-5:45 PM
New Insights into Reducing Cardiovascular Risk in Patients with Type 2 Diabetes
4:45 PM-5:45 PM
Fighting a Growing Epidemic: A Viral Hepatitis Update
 
 
 
CLOSE  X  
Registration and Breakfast
CLOSE  X  
Welcome and Opening Remarks
Room: Hall A, Level 1
CLOSE  X  
Mission Control: Professionalism to Medicine
Room: Hall A, Level 1
This presentation will look at your patient as a mission, with a very critical outcome, and how to get it right; the first time and every time. Dr. Musgrave will give a dramatic multimedia story composed of real life scenarios which will illustrate lessons and principles that are relevant and applicable to frontline patient care. Dr. Musgrave has lived such scenarios and the principles extracted from ones experiences can be so clear and comprehensible that they are readily accepted and embraced leading to the rarity of being acted upon.
Learning Objectives:
  1. Consider care of all patients as an urgent mission with critical outcomes
  2. Lead your team to ensure optimal patient outcomes through spirit, ownership, and passion for the mission
  3. Apply the best practices, procedures, and processes to guarantee that your path to clinical success is the best available
Faculty:
  1. Story Musgrave, MD , MS (Bio)
CLOSE  X  
Networking Break and Additional Opportunities
CLOSE  X  
Type 2 Diabetes: An Algorithmic, Evidence-Based Approach to Management, Part 1
Room: Hall A, Level 1
Improve your individualization of combination therapy for glycemic control in your diabetic patient that takes into account the enitire patient support structure.
Learning Objectives:
  1. Differentiate among the drug classes’ pros and cons when considering combination non-insulin therapy for type 2 diabetes patients who are not at goal
  2. Customize combination therapy by taking into account a patient’s support system, health care resources and desire/ability to take an active role in his/her diabetes care
Faculty:
  1. Scott Joy, FACP, MD, Medical Director, The Colorado Health Foundation, High Street Primary Care, Presbyterian/St Luke's Medical CenterDenver, CO (Bio)
CLOSE  X  
Finding Clinical Value in EHR Meaningful Use
Room: Room 23, Level 2
Many physicians are warry of the time and resource commitment to implementing an EHR in their practice. This session will provide tangible examples of the value of EHRs and meaningful use in your practice, with suggestions of next steps in their use.
Learning Objectives:
  1. Describe how Meaningful Use was created and what it was designed to accomplish
  2. Identify examples creating value from EHRs and Meaningful Use
Faculty:
  1. Peter Basch, MD (Bio)
CLOSE  X  
Women’s Health Update: Clinical Pearls for Primary Care
Room: Room 23, Level 2
A review of the spectrum of common health concerns in postmenopausal women and their prevention and management.
Learning Objectives:
  1. Recognize and address common health concerns in postmenopausal women.
  2. Be proactive in taking preventive measures to reduce the risk of fall and significant morbidity in your elderly female patients
Faculty:
  1. Kelly Spratt, DO, FACC, FACP, Clinical Associate Professor of Medicine, University of PennsylvaniaPhiladelphia, PA (Bio)
CLOSE  X  
Type 2 Diabetes: An Algorithmic, Evidence-Based Approach to Management, Part 2
Room: Hall A, Level 1
Sequential insulin strategies recommended by the ADA/EASD will be reviewed and evidence-based insulin regimens will be provided that can be used to initiate treatment that gets type 2 diabetic patient to their A1c goals.
Learning Objectives:
  1. Understand the rationale for sequential insulin strategies recommended by ADA/EASD
  2. Apply evidence-based insulin regimens to get patients with type 2 diabetes to A1C goals
Faculty:
  1. Jack Leahy, MD, Professor of Medicine, Chief, Division of Endocrinology, Diabetes and Metabolism, The University of VermontColchester, VT (Bio)
CLOSE  X  
Lunch and Additional Opportunities
CLOSE  X  
Critical Caveats for Common Medications
Room: Room 23, Level 2
Case-based review of side effects and drug interations encountered with commonly used medications including proton pump inhibitors, triptans, antibiotics, anticoagulants, NSAIDs, and antidepressants.
Faculty:
  1. Douglas Paauw, MD, Professor of Medicine, Rothman Family Foundation, Endowed Chair in Patient-Centered Clinical Education, University of Washington School of MedicineSeattle, WA (Bio)
CLOSE  X  
Lung Sounds: A Primer on Pulmonary Auscultation
Room: Hall A, Level 1
This primer on pulmonary auscultation will permit you to identify various breath sounds and adventitious lung sounds, including those findings which have been described only recently, and link them to the scientific and literature validation that supports their clinical relevancy.
Learning Objectives:
  1. Recognize and identify various breath sounds and adventitious lung sounds, including those findings which have been described only recently.
  2. Link literature validation and scientific basis to those sounds and extra-sounds which are clinically relevant.
  3. Establish a clinico-pathologic correlation for sounds and extra-sounds and murmurs.
Faculty:
  1. Salvatore Mangione, MD, Associate Professor of Medicine, Jefferson Medical CollegePhiladelphia, PA (Bio)
CLOSE  X  
Thank You for Not Smoking
Room: Hall A, Level 1
This session will provide guidance on the use of office-based counseling and evidence-based pharmacotherapies to improve smoking cessation efforts.
Learning Objectives:
  1. Utilize office-based counseling to address tobacco use and encourage smoking cessation with every patient visit
  2. Employ effective pharmacotherapies with ongoing supportive resources to help patients stop smoking
Faculty:
  1. Nancy Rigotti, MD, Professor of Medicine, Department of Medicine, Harvard Medical SchoolBoston, MA, Associate Chief, General Medicine Division, Department of Medicine, Massachusetts General HospitalBoston, MA (Bio)
CLOSE  X  
Managing Transitions of Care Between the Hospital and Community
Room: Room 23, Level 2
Transition of patient care from the inpatient setting to the community/primary care setting contains a number of risks to patient safety. This session will identify those risks and provide strategies for effective management of patient care transition.
Learning Objectives:
  1. Identify common risks to patient safety that can occur during care transition from inpatient to community
  2. Describe strategies that should be considered for effective management of patient care transition
Faculty:
  1. Lauren Doctoroff, MD, Instructor, Harvard Medical SchoolBoston, MA, Hospitalist, Beth Israel Deaconess Medical CenterBoston, MA (Bio)
  2. Yul Ejnes, MD, Clinical Associate Professor of Medicine, The Warren Alpert School of Medicine, Brown University Medical SchoolNorth Providence, RI, Internist, Coastal Medical, Inc.Cranston, RI (Bio)
 
 EHR in Primary Practice | Tools, Tips and Cases to Maximize Usability in Your Office
6:30AM
 
7:00AM
 
7:30AM
 
8:00AM
 
8:30AM
 
9:00AM
 
9:30AM
 
10:00AM
 
10:30AM
 
11:00AM
 
11:30AM
 
12:00PM
 
12:30PM
 
1:00PM
 
1:30PM
 
2:00PM
 
2:30PM
 
3:00PM
 
6:30 AM-7:30 AM - Registration and Breakfast
 
 
 
7:30 AM-7:45 AM - Welcome and Opening Remarks
7:45 AM-8:45 AM
Mission Control: Professionalism to Medicine
 
 
 
8:45 AM-9:30 AM - Networking Break and Additional Opportunities
 
 
9:30 AM-10:30 AM
Type 2 Diabetes: An Algorithmic, Evidence-Based Approach to Management, Part 1
9:30 AM-10:30 AM
Finding Clinical Value in EHR Meaningful Use
 
 
 
10:30 AM-11:30 AM
Type 2 Diabetes: An Algorithmic, Evidence-Based Approach to Management, Part 2
10:30 AM-11:30 AM
Women’s Health Update: Clinical Pearls for Primary Care
 
 
 
11:30 AM-1:30 PM - Lunch and Additional Opportunities
 
 
 
 
 
 
 
1:30 PM-2:30 PM
Lung Sounds: A Primer on Pulmonary Auscultation
1:30 PM-2:30 PM
Critical Caveats for Common Medications
 
 
 
2:30 PM-3:30 PM
Thank You for Not Smoking
2:30 PM-3:30 PM
Managing Transitions of Care Between the Hospital and Community
 
 
 

Ticketed Events

Registration for symposia and presentation theaters will open on August 20, 2013.

Breakfast

CME Educational Symposia

6:15 AM-7:45 AM

Alzheimer’s Disease

Lunch Break

Non-CME Presentation Theater

11:35 AM-12:20 PM

Atrial Fibrillation / Stroke

Lunch

CME Educational Symposia

11:45 AM-1:15 PM

Alzheimer’s Disease

Lunch Break

Non-CME Presentation Theater

12:40 PM-1:25 PM

Diabetes SGLTs

12:40 PM-1:25 PM

Alzheimer’s Disease

Dinner

CME Educational Symposia

6:15 PM-7:45 PM

Alzheimer’s Disease

Morning Break

Non-CME Presentation Theater

9:00 AM-9:30 AM

Irritable Bowel Syndrome

9:00 AM-9:30 AM

Triglycerides

9:00 AM-9:30 AM

Alzheimer's Disease

Lunch Break

Non-CME Presentation Theater

11:35 AM-12:20 PM

DPP-4 Diabetes

11:35 AM-12:20 PM

Helicobacter Pylori

11:35 AM-12:20 PM

Atrial Fibrillation / Stroke

Lunch

CME Educational Symposia

11:45 AM-1:15 PM

Diabetes

Lunch Break

Non-CME Presentation Theater

12:40 PM-1:25 PM

Hereditary Angioedema

12:40 PM-1:25 PM

Pneumococcal Disease in Adults 50+

Morning Break

Non-CME Presentation Theater

9:00 AM-9:30 AM

Type 2 Diabetes

9:00 AM-9:30 AM

Alzheimer’s Disease

Lunch Break

Non-CME Presentation Theater

11:35 AM-12:20 PM

COPD

11:35 AM-12:20 PM

Atrial Fibrillation / Stroke

11:35 AM-12:20 PM

Obesity

Lunch

CME Educational Symposia

11:45 AM-1:15 PM

Rheumatologic Disease

Lunch Break

Non-CME Presentation Theater

12:40 PM-1:25 PM

Overactive Bladder

12:40 PM-1:25 PM

Asthma

CLOSE  X  
Updates on the Diagnosis and Management of Alzheimer’s Disease Screening, Imaging, and Emerging Treatment Strategies
Room: Room 7, Level 1
Learning Objectives:
  1. Describe the pathophysiologic underpinnings of Alzheimer’s disease, including the role of amyloid ß
  2. Identify patients with risk factors and clinical symptoms that suggest a more formal evaluation for Alzheimer’s disease is warranted
  3. Employ new diagnostic criteria for mild cognitive impairment and dementia due to Alzheimer’s disease from the nation Institute on Aging - Alzheimer’s Association
  4. Discuss options for biomarker testing and brain imaging in patients who are being evaluated for Alzheimer’s disease
  5. Evaluate emerging therapeutic approaches that target aberrant amyloid production and deposition in patients with Alzheimer’s disease
Faculty:
  1. Adam Fleisher, MAS , MD, Director of Imaging, Banner Alzheimer's InstitutePhoenix, AZ, Medical Director, Alzheimer's Disease Cooperative StudyPhoenix, AZ, Associate Professor, Department of Neurosciences, University of CaliforniaSan Diego, CA
  2. Michael Rafii, MD, PhD, Director, Memory Disorders Clinic, University of California, San Diego Perlman Ambulatory Care CenterLa Jolla, CA, Assistant Professor of Neurosciences, University of California, San DiegoSan Diego, CA
  3. Eric Tangalos, MD, FACP, Professor of Medicine, Mayo ClinicRochester, MN
  4. Dennis Selkoe, MD, The Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical SchoolBoston, MA, Co-Director, Center for Neurologic Diseases, Department of Neurology, Brigham and Women's HospitalBoston, MA
The CME activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
CLOSE  X  
Reduction of Ischemic Stroke Risk vs Warfarin in Non-valvular Atrial Fibrillation
Brought to you by: Boehringer Ingelheim Pharmaceuticals, Inc..
Room: Theater 2
Faculty:
  1. Richard Bernstein, MD, PhD
CLOSE  X  
Updates on the Diagnosis and Management of Alzheimer’s Disease Screening, Imaging, and Emerging Treatment Strategies
Room: Room 7, Level 1
Learning Objectives:
  1. Describe the pathophysiologic underpinnings of Alzheimer’s disease, including the role of amyloid ß
  2. Identify patients with risk factors and clinical symptoms that suggest a more formal evaluation for Alzheimer’s disease is warranted
  3. Employ new diagnostic criteria for mild cognitive impairment and dementia due to Alzheimer’s disease from the nation Institute on Aging - Alzheimer’s Association
  4. Discuss options for biomarker testing and brain imaging in patients who are being evaluated for Alzheimer’s disease
  5. Evaluate emerging therapeutic approaches that target aberrant amyloid production and deposition in patients with Alzheimer’s disease
Faculty:
  1. Adam Fleisher, MAS , MD, Director of Imaging, Banner Alzheimer's InstitutePhoenix, AZ, Medical Director, Alzheimer's Disease Cooperative StudyPhoenix, AZ, Associate Professor, Department of Neurosciences, University of CaliforniaSan Diego, CA
  2. Michael Rafii, MD, PhD, Director, Memory Disorders Clinic, University of California, San Diego Perlman Ambulatory Care CenterLa Jolla, CA, Assistant Professor of Neurosciences, University of California, San DiegoSan Diego, CA
  3. Eric Tangalos, MD, FACP, Professor of Medicine, Mayo ClinicRochester, MN
  4. Dennis Selkoe, MD, The Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical SchoolBoston, MA, Co-Director, Center for Neurologic Diseases, Department of Neurology, Brigham and Women's HospitalBoston, MA
The CME activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
CLOSE  X  
Exposing Sodium Glucose Cotransporters (SGLTs): A Hidden Contributor To Persistent Hyperglycemia in Type 2 Diabetes
Brought to you by: Boehringer Ingelheim & Eli Lilly.
Room: Theater 1
Faculty:
  1. Rosemarie Lajara, MD
CLOSE  X  
Cholinergic Inhibition Across All Stages of Alzheimer’s Disease
Brought to you by: Novartis Pharmaceuticals.
Room: Theater 2
Key product efficacy, safety, and dosing information from recent pivotal studies will be discussed. Attendees will also gain insights into the progression of Alzheimer’s disease and treatment goals for managing patients.
Faculty:
  1. George Grossberg, MD
CLOSE  X  
Updates on the Diagnosis and Management of Alzheimer’s Disease Screening, Imaging, and Emerging Treatment Strategies
Room: Room 7, Level 1
Learning Objectives:
  1. Describe the pathophysiologic underpinnings of Alzheimer’s disease, including the role of amyloid ß
  2. Identify patients with risk factors and clinical symptoms that suggest a more formal evaluation for Alzheimer’s disease is warranted
  3. Employ new diagnostic criteria for mild cognitive impairment and dementia due to Alzheimer’s disease from the nation Institute on Aging - Alzheimer’s Association
  4. Discuss options for biomarker testing and brain imaging in patients who are being evaluated for Alzheimer’s disease
  5. Evaluate emerging therapeutic approaches that target aberrant amyloid production and deposition in patients with Alzheimer’s disease
Faculty:
  1. Adam Fleisher, MAS , MD, Director of Imaging, Banner Alzheimer's InstitutePhoenix, AZ, Medical Director, Alzheimer's Disease Cooperative StudyPhoenix, AZ, Associate Professor, Department of Neurosciences, University of CaliforniaSan Diego, CA
  2. Michael Rafii, MD, PhD, Director, Memory Disorders Clinic, University of California, San Diego Perlman Ambulatory Care CenterLa Jolla, CA, Assistant Professor of Neurosciences, University of California, San DiegoSan Diego, CA
  3. Eric Tangalos, MD, FACP, Professor of Medicine, Mayo ClinicRochester, MN
  4. Dennis Selkoe, MD, The Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical SchoolBoston, MA, Co-Director, Center for Neurologic Diseases, Department of Neurology, Brigham and Women's HospitalBoston, MA
The CME activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
CLOSE  X  
A Clinical Review of LINZESS
Brought to you by: Forest Pharmaceuticals, Inc..
Room: Theater 1
Faculty:
  1. Colin Howden, MD (Bio)
CLOSE  X  
VASCEPA® A Therapy for the Treatment of Severe Hypertriglyceridemia
Brought to you by: Amarin Pharma, Inc..
Room: Theater 3
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
Faculty:
  1. Gregory Pokrywka, MD, NCMP , FACP , FNLA, Assistant Professor of Medicine, Johns Hopkins University School of MedicineBaltimore, MD, Director, Baltimore Lipid CenterBaltimore, MD (Bio)
CLOSE  X  
A Different Approach to Alzheimer's Disease: Axona® as an Alternate Fuel for the Brain
Brought to you by: Accera, Inc..
Room: Theater 2
Faculty:
  1. Steven Schechter, MD
CLOSE  X  
Improving Glycemic Control Through DPP-4 Inhibition: Treatment Considerations for Adult Patients with Type 2 Diabetes
Brought to you by: Boehringer Ingelheim & Eli Lilly.
Room: Theater 1
Faculty:
  1. Elena Christofides, MD
  2. Debbie Hinnen, ARNP , BC-ADM , FAAN
CLOSE  X  
Helicobacter pylori: From Diagnosis to Management
Brought to you by: OAPI - Medical Device Division .
Room: Theater 3
Faculty:
  1. Adam Elfant, MD
CLOSE  X  
A Paradigm Shift In The Treatment of Thrombosis
Brought to you by: Janssen Pharmaceuticals, Inc..
Room: Theater 2
Faculty:
  1. Scott Kaatz, DO, FACP
CLOSE  X  
New Avenues in Insulin Therapy: Overcoming Roadblocks in Type 2 Diabetes
Room: Room 29, Level 2
Learning Objectives:
  1. Identify 3 priorities of blood glucose pattern management in T2DM
  2. Calculate starting and titration basal insulin doses for patients with T2DM
  3. Explain why avoidance of hypoglycemia should be the highest management priority in T2DM
  4. Compare and contrast the benefits and limitations of stepwise prandial insulin initiation vs premixed insulin initiation in T2DM
  5. Review recent data on investigational insulin therapies
Faculty:
  1. James Gavin, III, MD, PhD, Clinical Professor of Medicine, Emory University School of MedicineAtlanta, GA, CEO & Chief Medical Officer, Healing Our Village, IncAtlanta, GA (Bio)
  2. Davida Kruger, MSN , BC-ADM , APRN, Certified Nurse Practitioner, Division of Endocrinology, Diabetes, Bone and Mineral Disorders, Henry Ford Health System Detroit, MI
  3. Thomas Repas, DO, FACP, FACE, CDE, FNLA , FACOI, Clinical Assistant Professor, Department of Internal Medicine, Sanford School of Medicine, University of South DakotaRapid City, SD
The CME activity is supported by an educational grant from Novo Nordisk Inc..
CLOSE  X  
Inflammatory Back Pain Recognition and Diagnosis
Brought to you by: AbbVie.
Room: Theater 1
Faculty:
  1. Lori Siegel, MD
CLOSE  X  
Pneumococcal Pneumonia and Invasive Disease in Adults: Help Protect Your Patients Aged 50+
Brought to you by: Pfizer Inc..
Room: Theater 2
Faculty:
  1. Jorge Parada, MD
CLOSE  X  
Consider the Role of the Kidney in Type 2 Diabetes Mellitus
Brought to you by: Janssen Pharmaceuticals, Inc..
Room: Theater 2
Faculty:
  1. Timothy Reid, MD
CLOSE  X  
Emerging Trends in Alzheimer’s Disease Management: Namenda™ XR—a Treatment Option for Moderate to Severe Patients
Brought to you by: Forest Pharmaceuticals, Inc..
Room: Theater 1
Faculty:
  1. Adam Sky, MD
CLOSE  X  
COPD Care: Insights on Treatment Options An Open Gallery Event
Room: Theater 4
Faculty:
  1. David Bell, MB, FACE, FRCP
  2. Adam Friedlander, MD , MSc
CLOSE  X  
Helping Manage Stroke Risk in Patients with NVAF
Brought to you by: Bristol-Myers Squibb & Pfizer Inc..
Room: Theater 1
Faculty:
  1. Bruce Stambler, MD
CLOSE  X  
A Novel Treatment Option for Chronic Weight Management
Brought to you by: Eisai, Inc..
Room: Theater 2
Faculty:
  1. F. Wilford Germino, FASH, MD, FACP (Bio)
CLOSE  X  
Identifying and Managing Rheumatologic Disease in the Primary Care Setting
Room: Room 29, Level 2
Learning Objectives:
  1. Describe the natural history of RA and its impact on a patient’s quality of life in terms of disability, productivity, and ability to perform activities of daily living
  2. Define the criteria for the diagnosis of RA and the appropriate clinical and laboratory work-up to establish disease severity and activity
  3. Outline the evidence-based guidelines for the optimal management of patients with RA, with both conventional DMARDs and biologic agents
  4. Evaluate the treatment-associated adverse events (TAAEs) of conventional DMARDs and biologic agents in RA, and their management
Faculty:
  1. Sergio Schwartzman, MD, Franchellie M. Caldwell Associate Professor of Medicine, Weill Medical College of Cornell UniversityNew York, NY, Director of the Center for Innovative and Biologic Therapy, Hospital for Special SurgeryNew York, NY
The CME activity is supported by an educational grant from AMGEN.
CLOSE  X  
A Case-Based Approach to Treating OAB: Including Landmark Study Results
Brought to you by: Pfizer Inc..
Room: Theater 2
Faculty:
  1. Steven Maislos, MD
CLOSE  X  
Individualizing Treatment for Your Asthma and Exercise-Induced Bronchospasm Patients
Brought to you by: Teva Respiratory.
Room: Theater 1
Faculty:
  1. Juanita Mora, MD

Accreditation

These educational programs are conceived and created in accordance with Accreditation Council for Continuing Medical Education (ACCME) Accreditation Criteria, the ACCME Standards for Commercial Support, and ACCME Policies. Pri-Med faculty hail from a variety of institutions and participate in content development, along with pmiCME’s Advisory Boards and its expert review partner, Tufts Health Care Institute. All final decisions about program content are the responsibility of pmiCME.

Primary Care Updates
October 15, 2013
Credits Type Accreditation Statement Designation Statement
4.5 AMA PRA Category 1 Credits™ pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. pmiCME designates this live educational activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
4.5 AAFP This Live activity, Primary Care Updates, with a beginning date of 10/15/2013, has been reviewed and is acceptable for up to 4.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Integrated Approaches to Cardiometabolic Care
October 15, 2013
Credits Type Accreditation Statement Designation Statement
4.75 AMA PRA Category 1 Credits™ pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. pmiCME designates this live educational activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
4.75 AAFP This live activity, Integrated Approaches to Cardiometabolic Care, with a beginning date of 10/15/2013, has been reviewed and is acceptable for up to 4.75 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Updates—Track One
October 16, 2013
Credits Type Accreditation Statement Designation Statement
6.5 AMA PRA Category 1 Credits™ pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. pmiCME designates this live educational activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
6.5 AAFP This live activity, Primary Care Updates – Track 1, with a begin date of 10/16/2013, has been reviewed and is acceptable for up to 6.5 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
6.5 AANP pmiCME is approved as a provider of nurse practitioner continuing education programs by the American Association of Nurse Practitioners. AANP Provider number 040308. This program has been approved for 6.5 contact hours of continuing education (which includes 3.250 hours of pharmacology).
Primary Care Updates—Track Two
October 16, 2013
Credits Type Accreditation Statement Designation Statement
6.75 AMA PRA Category 1 Credits™ pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. pmiCME designates this live educational activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pending AAFP Application for CME credit has been filed with American Academy of Family Physicians. Determination of credit is pending.
6.75 AANP pmiCME is approved as a provider of nurse practitioner continuing education programs by the American Association of Nurse Practitioners. AANP Provider number 040308. This program has been approved for 6.75 contact hours of continuing education (which includes 3.375 hours of pharmacology).
Primary Care Updates—Track Three
October 16, 2013
Credits Type Accreditation Statement Designation Statement
7 AMA PRA Category 1 Credits™ pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. pmiCME designates this live educational activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
7 AAFP This live activity, Primary Care Updates – Track 3, with a begin date of 10/16/2013, has been reviewed and is acceptable for up to 7 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
7 AANP pmiCME is approved as a provider of nurse practitioner continuing education programs by the American Association of Nurse Practitioners. AANP Provider number 040308. This program has been approved for 7 contact hours of continuing education (which includes 3.500 hours of pharmacology).
Annual Conference
October 17—19, 2013
Credits Type Accreditation Statement Designation Statement
19 AMA PRA Category 1 Credits™ pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. pmiCME designates this live educational activity for a maximum of 19 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
19 AAFP This live activity, Midwest Annual Conference, with a begin date of 10/17/2013-10/19/2013, has been reviewed and is acceptable for up to 19 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
19 AANP pmiCME is approved as a provider of nurse practitioner continuing education programs by the American Association of Nurse Practitioners. AANP Provider number 040308. This program has been approved for 19 contact hours of continuing education

Keynote Speakers

Michael Dansinger, MD (Read Bio)

Presenting on:

Christine Sinsky, MD

Medical Associates Clinic and Health Plans, Dubuque, IA

Presenting on:

Thomas Sinsky, MD

Medical Associates Clinic and Health Plans, Dubuque, IA

Presenting on:

Story Musgrave, MD, MS (Read Bio)

Presenting on:

Exhibit Hall

Pri-Med Exhibit Hall

Hours
Thursday, October 17 8:30am–2:30pm
Friday, October 18 8:30am–2:30pm
Saturday, October 19 8:30am–2pm

The Pri-Med Exhibit Hall is your chance to learn about and compare over 175 of the health care industry’s latest products, treatments, and technologies in one place.


Spend your time in the Exhibit Hall talking to company representatives, evaluating new options, and making purchasing decisions for your practice—all things you do not have time for in your daily schedule. 

Attendee Badge Information

Please Note: As a Pri-Med registrant, you will receive a badge and an Attendance Scan Card, which will have bar codes programmed with your name, address, and professional discipline. You will scan your bar code at the appropriate stations to obtain CME credit or nursing contact hours.

Scanning your card at an exhibit booth or non-CME activity gives the sponsor permission to use your contact information for future correspondence.

Pri-Med Midwest Mobile App--get it today!

Exhibit Floor Highlights

Presentation Theaters

Join us for an informative snack break, lunch, or dinner discussion about the latest clinical information as it relates to a specific disease state.

Lunchtime workshops in the Presentation Theaters will focus on ways to boost revenue by adding ancillary products and services to your practice. Come and learn from some of the leading experts in the industry.

Exhibitor List

Company Name Booth Number
Accera, Inc. 622
AltaPoint Data Systems 423
Amarin Pharma, Inc. 611
American Association of Clinical Endocrinologists 117
American Diabetes Association 210
American Latex Allergy Association (ALAA) 307
Army National Guard 310
Atherotech 107
Availity LLC 425
Boehringer Ingelheim Pharmaceuticals, Inc 623
Calmoseptine 718
Chromogenex 526
COPD Foundation 208
CryoSurgery, Inc 106
Doximity 410
Elsevier Medical Books 807
Genova Diagnostics, Inc 113
HAE: Learn About It, Talk About It 219
Health Diagnostic Laboratory 316
Horizon Pharma USA, Inc 619
Infinite Therapeutics 322
Laclede Inc 309
MediTouch EHR / HealthFusion 231
MPR 108
Novartis Pharmaceuticals Corporation 717
Omron Healthcare 111
Pfizer Inc. 723
Pri-Med Recharge Lounge 730
Qiagen, Inc. 216
Scarf King 123
Summit Doppler / Wallach Surgical Devices 716
Televox Software, Inc. 206
The Gideons International 222
Ultimate Creations 126
ViroPharma Incorporated 406
Well Med Global 527
Xenna Corp 217
Company Name Booth Number
Aegis Sciences Corporation 207
Alzheimers Association 408
Amazing Charts 323
American College of Physicians 330
American Express Open 224
Apogee Physicians 233
AstraZeneca 506
Auxilium Pharmaceuticals, Inc. 810
Bionix 823
Boston Heart Diagnostics 522
Carlson Laboratories 706
Concentra 530
CryoProbe 607
Daiichi Sankyo, Inc. 306
Eisai, Inc. 531
Forest Pharmaceuticals, Inc. 515
GlaxoSmithKline 411
Hawaiian Moon 227
Hemosure Inc. 314
HydraFacial MD® - Edge Systems Corp. 617
Janssen Pharmaceuticals, Inc. 315
Lippincott Williams & Wilkins 819
Micro Direct, Inc. 211
Neilmed Pharmaceuticals, Inc. 711
OAPI- Medical Device Division 707
Pamlab, LLC 525
Pfizer Inc. 831
Pri-Med Visitor Center 110
Ringadoc 431
Shader Productions 326
Take Care Health Systems 624
Teva Respiratory 626
The Wall Street Journal 209
Verathon Medical 523
Vital Nutrients 811
Western Systems Research 311
Start:  End: 
Expand Expand Instructions Print PrintMap

Travel Arrangements

Meeting Location

Donald E. Stephens Convention Center
5555 North River Road
Rosemont, IL 60018
(847) 692-2220

Hotel Accommodations